The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

Suzhou ,Jiangsu ,China ,Macau ,Hong Kong ,Li Wang ,Jiangxi ,Shanghai ,Taiwan ,Rhui Zhou ,Guangdong ,United States ,Chinese ,Ben Basil ,Adimab Incyte ,Michael Yu ,Innovent Biologics ,Eli Lilly ,Md Anderson Cancer Center ,Cancer Communications ,National Medical Products Administration ,Radiographic Review Committee ,Prnewswire Innovent Biologics Inc ,Oncology Department Of Shanghai Chest Hospital ,National Reimbursement Drug List ,Company Lilly ,Innovent Biologics Inc ,Incyte Corporation ,Journal Of The National Cancer Center ,International Journal Of Nanomedicine ,New Drug Application ,Independent Radiographic Review Committee ,Lancet Oncology ,Lancet Respiratory Medicine ,Oncology Department ,Shanghai Chest Hospital ,Healthy China ,Senior Vice President ,General Manager ,Lilly China ,Lilly Corporate Senior Vice President ,China Drug Development ,Medical Affairs Center ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Mainland China ,Respir Med May ,National Cancer Center ,